Lidocaïne Adrenaline Aguettant

Lidocaine Hydrochloride and Epinephrine Bitartrate, the active ingredient in Lidocaïne Adrenaline Aguettant, is a local anesthetic presented as a sterile solution for injection for epidural, infiltration and perineural use. It provides rapid onset of numbness and prolongs the anesthetic effect for adult patients undergoing surgical or diagnostic procedures.

GNH USA supplies Lidocaïne Adrenaline Aguettant as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lidocaïne Adrenaline Aguettant, a combination local anesthetic, is employed in procedures that require regional or local anesthesia.

Surgical procedures: provides rapid onset anesthesia and prolongs duration for incision and excision. Infiltration anesthesia: numbs targeted tissue for minor surgeries or dental work. Epidural analgesia: delivers analgesia for labor or postoperative pain management. Dental procedures: offers quick oral tissue numbness for extractions and restorative work. Orthopedic surgery: facilitates muscle and joint anesthesia during minimally invasive interventions. Cesarean section analgesia: supports epidural analgesia for labor and delivery.

Adverse reactions may occur following administration of the combination product.

Common Side Effects: - Transient burning or stinging at the injection site - Mild dizziness or light‑headedness - Temporary tachycardia - Elevated blood pressure - Nausea or mild vomiting - Localized swelling or erythema

Serious or Rare Side Effects: - Anaphylactic or severe allergic reaction - Cardiac arrhythmias, including ventricular fibrillation - Seizures or convulsions - Methemoglobinemia - Persistent hypotension - Severe hypertension with reflex bradycardia

When using Lidocaïne Adrenaline Aguettant, clinicians should observe several safety measures.

Allergy assessment: avoid in patients with known hypersensitivity to lidocaine or epinephrine. Cardiovascular status: use cautiously in individuals with uncontrolled hypertension or arrhythmias. Pregnancy: evaluate risk‑benefit; limited data are available for use during pregnancy. Drug interactions: review concomitant beta‑blockers, MAO inhibitors, and antiarrhythmic agents. Dosage adjustment: consider reduced doses in elderly or patients with hepatic impairment. Store below 25°C: keep in the original container, protect from moisture and light.

Lidocaïne Adrenaline Aguettant may interact with several medicines; monitoring is essential.

Major Interactions (Avoid): - Beta‑blockers: can potentiate epinephrine‑induced hypertension and bradycardia. - Monoamine oxidase inhibitors (MAOIs): increase risk of hypertensive crisis with epinephrine. - Class I antiarrhythmics (e.g., quinidine): may enhance lidocaine toxicity.

Moderate Interactions (Monitor Closely): - Diuretics: may raise plasma lidocaine concentrations. - Tricyclic antidepressants: additive central nervous system toxicity. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may increase bleeding tendency due to vasoconstriction.